Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALLGregory W. Roloff, George Yaghmour, Evan C. Chen et al.|Journal of Clinical Oncology|2024Cited by 36
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALLIbrahim Aldoss, Betsy Blunk, Gregory W. Roloff et al.|Blood Advances|2024Cited by 12
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K. Valtis, Jae H. Park, Chenyu Lin et al.|Blood Advances|2025Cited by 3
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and AboveIbrahim N. Muhsen, Kristen M. O'Dwyer, Anjali S. Advani et al.|Blood|2024Cited by 3
Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysisYannis K. Valtis, Karamjeet Sandhu, Rawan Faramand et al.|Blood|2025Cited by 2